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The brain-speciﬁc angiogenesis inhibitor 1 gene has been isolated in an attempt to ﬁnd fragments with p53 functional binding
sites. As reported herein and by others, brain-speciﬁc angiogenesis inhibitor 1 expression is present in some normal tissues,
but is reduced or lost in tumour tissues. Such data and its particular structure prompted the hypothesis that brain-speciﬁc
angiogenesis inhibitor 1 may act as a mediator in the local angiogenesis balance. We herein demonstrate that brain-speciﬁc
angiogenesis inhibitor 1 over-expression suppresses tumour angiogenesis, delaying signiﬁcantly the human tumour growth in
immunodeﬁcient mice. The inhibitory effect of brain-speciﬁc angiogenesis inhibitor 1 was documented using our intravital
microscopy system, strongly implicating brain-speciﬁc angiogenesis inhibitor 1 as a mediator in the control of tumour
angiogenesis. In contrast, in vitro tumour cell proliferation was not inhibited by brain-speciﬁc angiogenesis inhibitor 1
transfection, whereas some level of cytotoxicity was assessed for endothelial cells. Immunohistochemical analysis of tumour
samples conﬁrmed a reduction in the microvessel density index in brain-speciﬁc angiogenesis inhibitor 1-overexpressing
tumours. At messenger level, moderate changes could be detected, involving the down-regulation of vascular endothelial
growth factor and collagenase-1 expression. Furthermore, brain-speciﬁc angiogenesis inhibitor 1 expression that was lost in a
selection of human cancer cell lines could be restored by wild-type p53 adenoviral transfection. Brain-speciﬁc angiogenesis
inhibitor 1 should be considered for gene therapy and development of efﬁcient drugs based on endogenous antiangiogenic
molecules.
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In recent years, the work of many cancer research groups has been
oriented toward the understanding of the events that take place at
the cellular and molecular level associated with the process of
angiogenesis. It has been widely accepted that tumour growth and
progression are dependent on angiogenesis (Folkman, 1971), a
process in which numerous factors have been found to be involved.
Moreover, recent evidence points toward the implication of genetic
alterations commonly present in pancreatic cancer, such as those
involving p16 or p53, in the ‘switching’ on of angiogenic phenotypes
(Harada et al, 1999; Nishizaki et al, 1999). For example, transduc-
tion of wild-type p53 in a mutant p53-expressing human lung
cancer cell via a recombinant adenovirus vector was demonstrated
to reduce the tumour growth in vivo, in part by a bystander effect
mediated by the antiangiogenesis mechanism (Nishizaki et al, 1999).
This effect has been attributed to the ability of p53 to reduce the
expression of the endogenous angiogenic factor, vascular endothe-
lial growth factor (VEGF) and enhance the expression of a newly
described antiangiogenic factor, brain-speciﬁc angiogenesis inhibi-
tor – BAI1 (Nishimori et al, 1997). Several other mechanisms
affecting tumour angiogenesis have also been presumed, such as
the induction of maspin, a member of serpin family (Zhang et al,
2000; Zou et al, 2000), and of thrombospondin 1 (Demeron et al,
1994). BAI1 has been isolated and characterized by Nishimori and
co-workers as a gene that is transactivated by p53. It has been
proposed to be a member of a novel family of seven-span trans-
membrane receptors that also includes BAI2 and BAI3, cloned
and described by Shiratsuchi et al (1997). The extracellular region
of BAI1 uniquely encompasses ﬁve thrombospondin type I repeats
and also one RGD (Arg-Gly-Asp) motif, which can be recognized
by integrins. Due to its structure, BAI1 has been considered as a
inhibitor of angiogenesis and a candidate for the glioma-derived
angiogenesis inhibitory factor (GD-AIF), previously described by
Van Meir et al (1994). Furthermore, in subsequent reports, BAI1
has been found to be absent or signiﬁcantly reduced in glioblasto-
mas (Nishimori et al, 1997), but also in many colorectal
(Fukushima et al, 1998; Yoshida et al, 1999), breast cancers (Nishi-
zaki et al, 1999), and lung cancers (Hatanaka et al, 2000), as
compared to the extraneoplastic tissues. This suggests that in these
tumours there is a correlation between the loss of its expression and
the angiogenic response. Although the BAI1 gene structure and
associated proteins have been comprehensively described (Nishi-
mori et al, 1997; Shiratsuchi et al, 1998a,b; Oda et al, 1999b), the
mechanism of its antiangiogenesis effect is still largely uncharacter-
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cellular region of BAI1 has been reported to inhibit angiogenesis
that was experimentally induced by basic FGF in rat cornea (Nishi-
mori et al, 1997). Moreover, a recombinant protein corresponding
to the TSP-1 type 1 repeats was found to be a strongly antiangio-
genic (Tolsma et al, 1993). Taken together, these results lead to
the presumption that BAI1 may be a mediator in the p53-signalling
pathway and to our hypothesis that BAI1 could be used to efﬁ-
ciently target the tumour-related angiogenesis.
Considering all the above-mentioned reports, in an attempt to
extend the study of the BAI1 effects on human tumours, we checked
the expression of this gene in pancreatic and colon cancer. In addi-
tion, we have investigated the interrelation between the presence of
BAI1 and human pancreatic tumour development, associated very
frequently with p53 mutation. To this end, BAI1 expression was ﬁrst
checked the in nine human pancreatic cell lines, all of which present
the loss of p53 integrity, and also in tumour tissue samples from 14
patients. Furthermore, by means of RT–PCR, we evaluated the
changes in proteolytic balance and endothelial cell mitogens incurred
by the BAI1 gene transfection in tumour cells. For the in vivo models,
we transfected BAI1 or the LacZ gene into a human pancreatic adeno-
carcinoma cell line (Panc-1) by means of adenoviral-mediated
transfer. Subcutaneous and skin chamber growth of wild-type and
transfected tumour cells were observed and measured. We have
analyzed visually the early human tumour angiogenesis with our
transparent chamber model in immunodeﬁcient mice. In short, this
is the ﬁrst report detailing the inhibitory effect of BAI1 on a human
tumour as applied by gene therapy.
MATERIALS AND METHODS
Cell lines and transfections
In order to check the expression of BAI1 we used six well-known
human pancreatic adenocarcinoma cell lines (Panc-1, MiaPaCa2,
AsPC-1, BxPC3, PCI35 and Su.Su.86), three cell lines established
in our department (PK-1, PK-8, and PK-9, Kobari et al, 1986),
and two widely-known colon cancer cell lines (T-84 and HT-29).
Panc-1, MiaPaCa2, and T-84 cells were maintained in DMEM
(Gibco, Tokyo, Japan) with glucose, the others in RPMI 1640
(Gibco, Tokyo, Japan), except for HT-29 cells that were cultured
in McCoy’s 5 A medium (Gibco, Tokyo, Japan). Finally, human
umbilical vein endothelial cells (HUVEC), cultured in 200S
medium (Kurabo, Tokyo, Japan) were used for in vitro experi-
ments. All culture media were supplemented with 10% foetal calf
serum, 100 U ml
71 penicillin and 0.1 mg ml
71 streptomycin and
cells were kept in a humidiﬁed 5% CO2 atmosphere at 378C. Gene
transfer in Panc-1 cells was achieved using replication-deﬁcient
recombinant adenoviral vectors encoding the full length cDNA of
BAI1, p53 or LacZ, at a multiplicity of infection (MOI) of 10 for
36 h, as described (Nishizaki et al, 1999). The p53 transfection
was performed also for two colon cancer cell lines. HUVECs were
infected with adenoviruses encoding BAI1 or LacZ. The reporter
gene transfer efﬁciency was assessed using beta-galactosidase stain-
ing, described elsewhere (Jiao et al, 1993).
Mice
Severe combined immunodeﬁcient mice (Fox Chase C.B-17/Icr-
SCID Jcl) 6–8-weeks-old were used in all experiments, and kept
in pathogen free conditions. Mice bearing dorsal skinfold chambers
were housed individually. This study was approved by the Ethical
Committee of Tohoku University Graduate School of Medicine.
We observed the United Kingdom Co-ordinating Committee on
Cancer Research (UKCCCR) guidelines for the welfare of animals
in experimental neoplasia.
In vitro and in vivo growth measurement
In order to evaluate the cytotoxic effects of BAI1 expression on
Panc-1 cells and on HUVECs, we performed MTT assays. One
thousand tumour cells were plated in a 96-well plate and infected
for 36 h with adenoviral vector encoding BAI1 using multiplicities
of infection from 0–200 (16 wells for each of the MOI used).
Media was changed after 36 h, and 5 days after infection, 10 ml
of sterile tetrazolium salt, MTT (3[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide, Sigma Chemical Co, St Louis,
MO, USA) was added to the wells and incubated for 4 h at
378C. Finally, 100 ml of 10% SDS were added, and after incubation
at 378C overnight, the plate was read at 490 nm. The in vitro
growth of 2610
5 of the Panc-1 transfectants (MOI 10) used for
in vivo experiments was compared to wild-type cells by crystal
violet (1%) staining at day 6.
Subcutaneous growth curves in NK-depleted SCID mice of
Panc-1 wild-type, Panc-1/BAI1, and Panc-1/LacZ (1610
6 cells,
n=5) were assessed by measuring the tumour volume using a calli-
per. Tumour volumes were estimated by the following formula:
V=D6d
260.4 (V=tumour volume D=largest dimension, and
d=smallest dimension).
Dorsal skin chamber model
Transparent chamber and in vivo microscopy system are reliable
means for evaluation of tumour angiogenesis (Lehr et al, 1993).
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Table 1 PCR condition
PCR product Primers
Number
of cycles
Annealing
temperature References
BAI1 5'-GGACTCATCCTGCGACGGTGTGA-3' 28 628C This study
3'-TGCATCCCTCAGGTCCTTCATGC-3'
MMP-1 5'-GACAGATTCTACATGCGCAC-3' 30 558C Iwasaka et al, 1996
5'-GTGGCCAATTCCAGGAAAGT-3'
uPA 5'-TCCCCGACTATACAGACCAT-3' 30 558C Iwasaka et al, 1996
5'-TCTCTTCCTTGGTGTGACTG-3'
ETS-1 5'-TATGGAATGTGCAGATGTCC-3' 25 558C Iwasaka et al, 1996
5'-ATCTCCTGTCCAGCTGATAA-3'
VEGF 5'-ATGAACTTTCTGCTCTCTTG-3' 30 558C Burchardt et al, 1999
3'-CACATCTGCAAGTACGTTC-5'
bFGF 5'-AAAACGGGGGCTTCTTCCT-3' 25 558C This study
3'-TGCCCAGTTCGTTTCAGTGC-5'
MSH2 5'-TGACTTCTCCAAGTTTCAGGA-3' 28 558C Takeshita et al, 1999
5'-CGAAGGACTTTTTCTTCCTTAC-3'
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manufactured by Aoba Science Ltd. (Sendai, Japan). Tumour
angiogenesis following implantation of wild-type Panc-1 or trans-
fectants (1610
6 cells) was observed biweekly for 24 days using a
Optiphoto 066 microscope (Nikon, Tokyo, Japan), a CCD camera
(TEC-470 Optronics Co. Chelmsford, MA, USA) attached to the
microscope, and the images were recorded on a video tape recorder
(Victor, Tokyo, Japan). The recorded data were analyzed off-line.
Semiquantitative RT–PCR
The expression of BAI1 in normal and tumour pancreatic tissue,
and in pancreatic and colon cancer cell lines was assessed by
RT–PCR. Total cellular RNA was extracted from a normal and
14 tumour pancreatic tissue samples, and from 1610
6 tumour cells
using RNeasy Mini Kit (Qiagen KK, Tokyo, Japan), then 10 mg
aliquots were reversed-transcribed using a RNease H Minus RT
(Toyobo Co., Tokyo, Japan), and 1 mg of the resultant cDNA
was ampliﬁed. Basic FGF, VEGF, MMP-1, ETS-1, and uPA were
also ampliﬁed. The ampliﬁcation of MSH2 was used as internal
control. The speciﬁc ampliﬁcation conditions are shown in Table
1. Finally, aliquots of 10 ml from the ampliﬁcation reactions were
electrophoresed on 2% agarose (FMC BioProducts, Rokland, ME,
USA) Tris-acetate EDTA gels and autoradiographed.
Antibodies and histopathology
Rabbit anti-asialo GM1 antibody (Wako, Japan) was administered
to SCID mice twice a week in order to block the non-speciﬁc
immunity conferred by the NK cells. Standard haematoxylin and
eosin staining was performed on 3–5 mm sections from parafﬁn-
embedded tumour samples. Immunostaining of endothelial cells
in tumour tissue was performed using rat anti-mouse PECAM-1
(CD31) antibody (BD Pharmingen, San Diego, CA, USA), as
described (Vlaykova et al, 1997). Tissue sections (three per
tumour) from control and transfectant tumours (n=5) were
stained, and capillaries (diameter 510 mm) were counted in 10
high magniﬁcation ﬁelds per section.
Statistical analysis
All experiments were performed in duplicate or triplicate. A two-
tailed student t-test was used for statistical analysis of comparative
data. Values of P50.05 were considered signiﬁcant.
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VEGF
B
M
B
M
MMP-1
MSH2
648bp (isoform 164)
514bp (isoform 120)
392bp
282bp
461bp
282bp
461bp
282bp
BAI1 NT T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14
Panc-1
LacZ p53 wt LacZ p53 wt LacZ wt p53 BAI1
T84 HT-29 Panc-1
wt BAI1 LacZ
Panc-1 Panc-1 Panc-1
A
B
C
Figure 1 RT–PCR results showed that the expression of BAI1 that could be detected in normal pancreatic tissue (NT) was completely lost in all samples
from pancreatic tumour tissue (T1 through T14) checked (A). On the other hand, strong BAI1 expression – designated B was conﬁrmed after the ade-
novirus-mediated transfer. Interestingly, some level of expression could be restored in Panc-1 tumour cells, as well as in two colon carcinoma cells (HT-29
and T84) upon transfection of wild-type p53, but not after LacZ adenoviral transfer in these cells (B). Ampliﬁcation for MSH-2 – designated M – was used
as internal control in all experiments. RT–PCR for VEGF and a duplex reaction using primers for MMP-1 and MSH-2 indicated a reduction in MMP-1 ex-
pression level, and to a limited extent, of VEGF, in human pancreatic adenocarcinoma cells Panc-1 after BAI1, but not after LacZ transfer (C).
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Expression of BAI1 in tissue and in tumour cells
Of particular signiﬁcance, as reported by others for colon and lung
tissues, we detected BAI1 expression at messenger level in the
normal pancreatic tissue, but not in any of the pancreatic and
colon adenocarcinoma cell lines or tumour tissues checked (Figure
1A,B). It is still unclear what type of cell is responsible for the
expression in these normal tissues. In addition, there is no docu-
mentation as yet about the predicted existence of a soluble form
of BAI1 upon cleavage of the extracellular region. A strong BAI1
expression could be conﬁrmed by RT–PCR in Panc-1/BAI1 cells,
but lacked completely in LacZ-transfected or wild-type Panc-1 cells.
Interestingly, after p53 adenoviral transfer, BAI1 expression was
induced in Panc-1 and in the two colon cancer cell lines, T-84
and HT29 (Figure 1B), but not in the LacZ transfectants. On the
other hand, the tumour cells used expressed an array of positive
regulators of angiogenesis. Speciﬁcally, we identiﬁed by Northern
blot and RT–PCR analysis the expression of several positive regu-
lators of angiogenesis and invasion: endothelial growth factors-
VEGF, bFGF, uPA, and a signal factor induced by the mitogens,
ETS-1, respectively (unpublished data). The expression in tumour
cells of some of these factors such as basic FGF, ETS-1, and uPA
appeared not to be affected by transfer of either the BAI1 or LacZ
gene (not shown). However, BAI1 induced a decrease in VEGF
level, as well as of that of interstitial collagenase 1 (MMP-1), the
only metalloproteinase expressed in Panc-1 cells. This was not
due to reporter gene transfection, as indicated by simple and
duplex RT–PCR for MMP-1 and MSH2 (Figure 1C).
In vitro tumour growth
After 6 days of culture, there was no difference between the growth
of parental Panc-1 cells and those of BAI1 or LacZ transfectants.
Crystal violet staining displayed a similar growth rate for Panc-1
cells and the Panc-1/BAI1 cells (MOI 10) used for in vivo studies
(not shown). Moreover, beta-galactosidase staining of LacZ trans-
fectants (MOI 10) conﬁrmed a very high infection rate (almost
90%) of the tumour cells by the adenoviral-mediated transfer.
Although no signiﬁcant cytotoxic effect of BAI1 on tumour cells
was observed by MTT assays, an antiproliferative effect after trans-
fection into HUVECs was indicated (Figure 2).
In vivo tumour growth
In contrast to wild-type Panc-1 and Panc-1/LacZ, which promoted
a rapid tumour growth, as shown by tumour measurements up to
day 24, the subcutaneous inoculation of Panc-1/BAI1 in immuno-
deﬁcient mice signiﬁcantly inhibited tumour growth (Figure 3).
After an initial onset of the tumour development, BAI1 presence
was able to suppress angiogenesis and inhibited potently tumour
growth. Despite the fact that expression of BAI1 in vivo after the
adenovirus transfer was presumably lost in time, the tumour
growth was delayed signiﬁcantly even at day 84, when the mice
were sacriﬁced, suggesting a bystander effect of BAI1. Although
tumours were not cured, their growth was restricted by BAI1
over-expression following adenoviral transfection to an extent
comparable to other strong angiogenesis inhibitors. There were
no side effects apparent in any of the mice used throughout the
experiments.
In vivo microscopy
Insights into the antiangiogenesis effect of BAI1 were gained by
observation of tumour-related angiogenesis in our simpliﬁed trans-
parent skin chamber model. Skin is a tissue with a high vascularity
and thus, this system using immunodeﬁcient mice and human
tumour cells allows a very accurate assessment of tumour angio-
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Figure 2 In vitro growth of tumour and endothelial cells after BAI1 trans-
fection. The MTT assay was performed in duplicate, and for each MOI, an
average of the optical density readings was calculated (+s.d., standard de-
viation). The reduction in optical density induced by adenoviral transfection
was used as a measure of viability, normalized to cells incubated in the ab-
sence of transfection (MOI 0), which were considered 100% viable. Viability
of cells at day 5 after transfection: (A) for Panc-1 tumour cells and (B) for
HUVECs.
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Figure 3 In vivo human tumour growth in NK-depleted SCID mouse.
Measurements up to day 24 after subcutaneous inoculation demonstrated
the very potent antiangiogenesis effect on tumours after BAI1 transfection,
translated to a signiﬁcant (*P50.05) delay in tumour growth compared to
the tumours in the wild-type and LacZ transfectant groups (average
tumours volume+s.d.).
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 490–496genesis. In particular, vessel sprouting and the establishment of a
tumour vessel network was observed surrounding and within the
LacZ-transfected or wild-type Panc-1 cell implants as early as day
14 following cell implantation. In contrast, Panc-1/BAI1 cell
implantation resulted in a signiﬁcantly lower level of vascularity
and the tumour appeared dormant after 2 weeks (Figure 4).
Histochemistry
Routine H&E staining revealed large areas of necrosis in the
samples from Panc-1/BAI1 tumours as well as a signiﬁcantly lower
vascularity as compared to the Panc-1 wild-type and Panc-1/LacZ
tumours after staining the tumour-related microvessels with
PECAM-1 (Figure 5). However, immunostaining showed no rele-
vant difference in the expression of gelatinases (MMP-2 and
MMP-9) between the three types of tumour (not shown).
DISCUSSION
Tumour cells organize into solid tumours and metastasize due to a
change from the normal phenotype in the local environment
toward an angiogenic one. This is a consequence of the prevalence
of proangiogenic factors compared to the antiangiogenic ones. We
demonstrated by means of RT–PCR and Northern blotting that
pancreatic and colon adenocarcinoma cells express various angio-
genic factors like the endothelial cell mitogens- VEGF and bFGF,
ETS-1 (documented as an angiogenic factor by Oda et al, 1999a),
as well as haemoxygenase 1 (unpublished data), which has been
recently found to induce angiogenesis (Deramaudt et al, 1998).
The presence of these factors is likely to mediate the growth and
invasion of these adenocarcinomas by induction of angiogenesis.
On the other hand, the expression of angiogenic factors in tumours
is paralleled by the decrease of the antiangiogenic factors. One of
them, the recently discovered BAI1 has now been detected in
normal pancreatic, colon and lung tissue, both at transcriptional
and protein level, as reported previously and in this study.
However, there was no detectable BAI1 expression in any of the
p53 defective pancreatic and colon cancer cell lines, nor in the
pancreatic tumour tissue samples that were examined. Nevertheless,
the wild-type 53 adenoviral-mediated transfer was able to restore
the BAI1 expression in all tumour cell lines checked. These features
displayed in pancreatic and colon cancer cells are in accordance
with previous reports that the lack of BAI1 expression correlated
with the p53 mutation-related tumour angiogenesis. However,
additional mechanisms seem to play a role in the regulation of
BAI1, as a wild-type p53 glioblastoma cell line – U87MG does
not express BAI1 (Nishimori et al, 1997). Nevertheless, expression
of BAI1 induced by adenoviral transfer in these cells did strongly
inhibit their growth in the transparent skin chamber compared
to parental cells, a feature that was not found after LacZ transfer
(unpublished observations).
Several lines of evidence presented in this study emphasize the
importance of the recently described BAI1 gene. The presence of
ﬁve thrombospondin type I repeats has been proposed as an expla-
nation for its antiangiogenic effects, taking into consideration the
effects on angiogenesis reported for other proteins containing these
repeats such as TSP-1, TSP-2, METH-1, and METH-2 (Vazquez et
al, 1999). Of particular interest is the fact that the BAI1 gene trans-
fer in tumour cells, similar to that of p53, seemed to change the
RNA level of the endothelial cell mitogen VEGF, but did it alter
other factors (bFGF, uPA, and ETS-1) implicated in the local
angiogenic and proteolitic balance. Moreover, as reported for
wild-type p53, BAI1 over-expression inhibited the expression of
collagenase-1 (MMP-1), which is known to be a positive regulator
of tumour angiogenesis (Sang, 1998), and was the only metallopro-
teinase we found to be expressed in Panc-1 cells. As yet, it is still
unclear at what regulatory level this inhibition occurs, since BAI1
did not change the levels of ETS-1, which was implicated in the
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5 Panc-1 wild-type (upper panels), Panc-1/BAI1
(middle panels), or Panc-1/LacZ (lower panels) cells at day 0 (A,E,I), day 3 (B,F,J), day 7 (C,G,K) and day 14 (D,H,L). BAI1 transfected tumour cells failed
to promote angiogenesis after 2 weeks, whereas the wild-type and LacZ transfected cells established a stable vascular network based on the normal
vasculature of the skin, in a similar time frame.
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(Iwasaka et al, 1996).
In vitro experiments revealed that BAI1 transfection resulted
in no detectable cytotoxic effect on tumour cells, but conﬁrmed
a level of cytotoxicity for endothelial cells, consistent with
previous reports (Nishizaki et al, 1999). In vivo, subcutaneous
and skin chamber implantation of Panc-1/BAI1 in NK-depleted
SCID mice strongly suppressed tumour growth, while wild-type
and LacZ-transfected tumours failed to do so. The immuno-
staining of tumour-related microvessels also showed a signiﬁcant
reduction of vessel density in Panc-1/BAI1, as compared to
Panc-1 or Panc-1/Lac-Z tumour tissue. By capturing and off-
line analysis of images from the transparent skin chamber, a
decrease of vascularity in Panc-1/BAI1 tumour was directly
observed and clearly indicated the inhibitory effect of BAI1
on angiogenesis.
Reported herein is also the observation that local overexpression
of BAI1 disables any localized angiogenesis to such an extent that is
able to induce an apparent state of dormancy in a transfected
pancreatic adenocarcinoma cell line. Thus, even though the tumour
cells were not killed, the tumour was unable to grow. One explana-
tion for this phenomenon may involve an antiproliferative effect
toward the endothelial cells, but the antitumour effects that occurs
in vivo may be also due to putative interactions of the extracellular
region of BAI1, since it is known to contain ﬁve thrombospondin
type I repeats and of a RGD motif that is recognized by integrins.
In addition, BAI1 inhibition of interstitial collagenase expression
may prevent the dissolution of the extracellular matrix. Matrix
metalloproteinase-1 (MMP-1) was found in other cells to be a
p53-target gene, subject to p53 repression, mediated in part by
associated protein 1 (Sun et al, 1999). We are currently investigat-
ing the MMP-1 protein level and activity in relation to BAI1 and
p53 expression.
Taken together, this data offers further evidence that BAI1 is
the candidate for the glioma-derived angiogenesis inhibitory
factor (GD-AIF). It appears that the presence of the integrin-
recognition motif RGD plays an important role in antiangio-
genesis mechanisms and therefore we are currently investigating
the effects of the transfer of BAI1 with a point mutation within
the RGD motif.
The loss of BAI1 expression plays a role in the tumour
angiogenesis-related cascade of events not only in brain-speciﬁc
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Panc-1/LacZ
Panc-1/BAI1
Panc-1 wt
02468
G
No. of capillaries per field
Figure 5 H&E staining of sections from Panc-1 (A), Panc-1/BAI11 (B), and Panc-1/LacZ 1 (C) tumours (magniﬁcation, 610). Large areas of necrosis in
the Panc-1/BAI1 tumour samples. Also, the expression of the endothelial cell marker CD31 in human Panc-1 (D), Panc-1/BAI11 (E), and Panc-1/LacZ (F)
tumours from immunodeﬁcient mice (magniﬁcation,640) showed a decreased vascular index (G) in the BAI1 transfectant tumour samples.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 490–496tumours, but also in other tumours types. These events are
generally associated with the loss of p53 integrity or function.
On the other hand, the overexpression of BAI1 inhibited
strongly the pancreatic tumour-related angiogenesis. Therefore,
since pancreatic carcinoma has a very poor prognosis after
surgery, chemotherapy, and radiation therapy, BAI1 should be
considered as a relevant candidate for future trials using this
type of molecules or peptides derived from them, that would
employ targeting of tumour angiogenesis as adjunctive or adju-
vant therapy.
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